Meta-analysis of two ERCC2 (XPD) polymorphisms, Asp312Asn and Lys751Gln, in breast cancer

Author： Pabalan Noel  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.124, Iss.2, 2010-11, pp. : 531-541

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

XPD Asp312Asn and Lys751Gln polymorphisms and breast cancer susceptibility: A meta-analysis

By Yan Yulan   Liang Hongjie   Light Morning   Li Taijie   Deng Yan   Li Meng   Li Shan   Qin Xue  

Tumor Biology, Vol. 35, Iss. 3, 2014-03 ,pp. : 1907-1915

Springer Publishing Company

Access to resources Recommend Favorite

XPD Lys751Gln and Asp312Asn polymorphisms and hepatocellular carcinoma susceptibility: A meta-analysis of 11 case-control studies in an Asian population

By        

Experimental and Therapeutic Medicine, Vol. 9, Iss. 6, 2015-01 ,pp. : 2406-2414

Spandidos Publications

Access to resources Recommend Favorite

The association between ERCC2 Asp312Asn polymorphism and breast cancer risk: a meta-analysis involving 22,766 subjects

By Yao Lei  

Breast Cancer Research and Treatment, Vol. 123, Iss. 1, 2010-08 ,pp. : 227-231

Springer Publishing Company

Access to resources Recommend Favorite

XPD Lys751Gln polymorphism and breast cancer susceptibility: a meta-analysis involving 28,709 subjects

By Qiu Li-Xin  

Breast Cancer Research and Treatment, Vol. 124, Iss. 1, 2010-11 ,pp. : 229-235

Springer Publishing Company

Access to resources Recommend Favorite

XPD Lys751Gln increases the risk of breast cancer

By          

Oncology Letters, Vol. 2, Iss. 1, 2011-01 ,pp. : 155-159

Spandidos Publications

Access to resources Recommend Favorite